source
- Roche drops anti-myostatin obesity drug after mid-stage trial shows limited weight lossRoche announced it will stop development of its anti-myostatin obesity candidate emugrobart after an interim analysis of the Phase 2 GYMINDA trial showed it is unlikely to produce meaningful weight…
- Novo Nordisk licenses weekly oral obesity peptide from Hengrui in up to $2.6 billion dealNovo Nordisk has signed a licensing agreement with China's Hengrui Pharma for a once‑weekly oral peptide, HRS‑1596, aimed at obesity and other metabolic conditions. Novo will pay $300 million upfr…